New Results
Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants
View ORCID ProfileCarolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen S. G. Dias, Jairo R. Temerozo, Aline de Paula D. Da Silva, Carine S. da Silva, André C. Ferreira, Mayara Mattos, Vinicius C. Soares, Filipe Pereira-Dutra, Milene D. Miranda, Debora F. Barreto-Vieira, Marcos Alexandre N. da Silva, Suzana S. Santos, Mateo Torres, Rajith K R Rajoli, Alberto Paccanaro, Andrew Owen, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Thiago Moreno L. Souza
doi: https://doi.org/10.1101/2021.07.21.451321
Carolina Q. Sacramento
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
7National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Natalia Fintelman-Rodrigues
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
7National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Suelen S. G. Dias
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
Jairo R. Temerozo
2National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Aline de Paula D. Da Silva
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
7National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Carine S. da Silva
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
7National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
André C. Ferreira
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
4Universidade Iguaçu, Nova Iguaçu, RJ, Brazil
7National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Mayara Mattos
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
7National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Vinicius C. Soares
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
5Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
Filipe Pereira-Dutra
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
Milene D. Miranda
6Laboratório de Vírus Respiratório e do Sarampo, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Debora F. Barreto-Vieira
8Laboratório de Morfologia e Morfogênese Viral, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Marcos Alexandre N. da Silva
8Laboratório de Morfologia e Morfogênese Viral, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Suzana S. Santos
9School of Applied Mathematics, Fundação Getulio Vargas, Rio de Janeiro, RJ, Brazil
Mateo Torres
9School of Applied Mathematics, Fundação Getulio Vargas, Rio de Janeiro, RJ, Brazil
Rajith K R Rajoli
10Centre of Excellence in Long acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
Alberto Paccanaro
9School of Applied Mathematics, Fundação Getulio Vargas, Rio de Janeiro, RJ, Brazil
11Department of Computer Science, Royal Holloway, University of London, Egham, United Kingdom
Andrew Owen
10Centre of Excellence in Long acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
Dumith Chequer Bou-Habib
2National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Patrícia T. Bozza
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
Thiago Moreno L. Souza
1Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
7National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Posted July 21, 2021.
Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants
Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen S. G. Dias, Jairo R. Temerozo, Aline de Paula D. Da Silva, Carine S. da Silva, André C. Ferreira, Mayara Mattos, Vinicius C. Soares, Filipe Pereira-Dutra, Milene D. Miranda, Debora F. Barreto-Vieira, Marcos Alexandre N. da Silva, Suzana S. Santos, Mateo Torres, Rajith K R Rajoli, Alberto Paccanaro, Andrew Owen, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Thiago Moreno L. Souza
bioRxiv 2021.07.21.451321; doi: https://doi.org/10.1101/2021.07.21.451321
Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants
Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen S. G. Dias, Jairo R. Temerozo, Aline de Paula D. Da Silva, Carine S. da Silva, André C. Ferreira, Mayara Mattos, Vinicius C. Soares, Filipe Pereira-Dutra, Milene D. Miranda, Debora F. Barreto-Vieira, Marcos Alexandre N. da Silva, Suzana S. Santos, Mateo Torres, Rajith K R Rajoli, Alberto Paccanaro, Andrew Owen, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Thiago Moreno L. Souza
bioRxiv 2021.07.21.451321; doi: https://doi.org/10.1101/2021.07.21.451321
Subject Area
Subject Areas
- Biochemistry (11745)
- Bioengineering (8751)
- Bioinformatics (29195)
- Biophysics (14971)
- Cancer Biology (12095)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14179)
- Epidemiology (2067)
- Evolutionary Biology (18306)
- Genetics (12245)
- Genomics (16802)
- Immunology (11867)
- Microbiology (28083)
- Molecular Biology (11592)
- Neuroscience (60965)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7339)
- Zoology (1651)